Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Ophthalmic Disease Model Development Service
Are you currently facing long, unpredictable drug development cycles and challenges in obtaining reliable preclinical data for ophthalmic therapies? Our NHP Ophthalmic Disease Model Development service helps you accelerate drug discovery and de-risk your pipeline. We achieve this through the creation and utilization of highly translational NHP models, bridging the gap between basic research and human clinical trials with unmatched precision and speed.
Overview of NHP Ophthalmic Disease Models
The journey from a promising therapeutic candidate to a market-ready drug is complex, especially for ophthalmic diseases. The intricate structure of the human eye, including its retina and optic nerve, is difficult to replicate in smaller animal species like rodents. Non-human primates, particularly macaques, serve as the gold standard for preclinical ophthalmology research due to their remarkable anatomical, physiological, and genetic similarities to humans. Their advanced visual systems, which include a macula, allow for the accurate modeling of complex human conditions like AMD, glaucoma, and IRDs.
What Our Service Is
Our NHP Ophthalmic Disease Model Development service provides a comprehensive platform for the preclinical evaluation of new treatments. We specialize in the creation and use of highly relevant NHP models that closely mimic human ophthalmic pathologies. Application scenarios:
- Gene Therapy Evaluation: We develop and apply genetic models using advanced techniques to test gene therapies for inherited retinal diseases.
- Drug and Biologics Efficacy Testing: We establish models of complex diseases such as glaucoma or retinal neovascularization (a key feature of AMD and diabetic retinopathy) to evaluate the efficacy of small molecules and biologics.
- Medical Device and Surgical Procedure Testing: We provide a stable and reliable in-vivo platform for testing the safety and effectiveness of new ophthalmic devices and surgical techniques.
Why Choose Us?
In the high-stakes world of drug development, every decision counts. The wrong preclinical model can lead to costly failures in clinical trials.
- Pain Point: The use of less-relevant animal models often results in unreliable data, leading to a high rate of clinical trial failure and significant financial losses.
- Benefit: Creative Biolabs provides a high-fidelity translational model that minimizes this risk. By using NHPs, we generate data with a high degree of predictability for human outcomes, increasing your confidence in a therapeutic candidate and reducing the time and cost to market.
Fig.1 Images of a 19-year-old healthy female monkey, comprising slit-lamp photographs, color fundus images, anterior segment OCT images, and posterior segment OCT images.1
Key Benefits of Our Service
Our approach is built on a foundation of scientific rigor, advanced resources, and a client-centric philosophy.
- Responsive and Efficient: We understand that time is of the essence. Our streamlined processes and dedicated project management ensure a rapid study start-up and timely execution, allowing you to meet your development milestones.
- Extensive NHP Resources: Creative Biolabs maintains most well-characterized NHP colonies, providing immediate access to healthy subjects and spontaneous disease models. This eliminates the long lead times often associated with finding suitable animals for your study.
- Unmatched Customization: Your project is unique. We offer fully customizable study designs that can be tailored to the specific mechanism of action, route of administration, and desired endpoints of your therapeutic. We collaborate with you to define the ideal model, from naturally occurring to genetically induced pathologies, for your specific needs.
- In-Depth Reporting: Our deliverables go beyond simple data tables. We include a wide range of metrics, from intraocular pressure (IOP) to retinal nerve fiber layer (RNFL) thickness, for a complete picture of therapeutic effect.
How Creative Biolabs' NHP Model Development Can Assist Your Project?
Our goal is to provide a clear, actionable pathway from concept to preclinical success. We offer a transparent, multi-stage workflow designed to streamline your project and deliver the specific solutions you need.
01
Required Starting Materials
02
Project Initiation and Study Design
03
Model Selection and Characterization
04
Dose Administration and Monitoring
05
Efficacy and Safety Assessment
06
Data Analysis and Reporting
Key Deliverables
- Comprehensive Study Report: A detailed, summary-level analysis of the study, methods, results, and conclusions.
- Raw Data Files: All raw data from ophthalmic measurements, imaging, and lab assays provided in a client-friendly format.
- Model Annotations: Detailed characterization of the disease model, including genetic or phenotypic annotations.
- High-Resolution Images and Videos: Annotated images from fundus photography, OCT, and angiography, providing visual evidence of therapeutic effects.
- Histopathology Slides and Analysis: Results from tissue-level analysis for safety and efficacy endpoints.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: How do NHP ophthalmic models compare to other animal models, like rodents?
A: Rodent models are useful for initial screening, but their ocular anatomy differs significantly from humans. NHPs, with their advanced visual systems and a fovea similar to our own, provide a far more accurate and predictive model for human disease. This translational relevance is critical for de-risking your project before expensive clinical trials.
Q: What is the benefit of using a naturally occurring disease model versus a genetically engineered one?
A: Both models have distinct advantages. Naturally occurring models offer a realistic representation of disease progression but can be rarer to find. Genetically engineered models, especially those using cutting-edge tools, provide precise control over the disease mechanism, allowing for targeted gene therapy development. We can help you select the most appropriate model based on your therapeutic's mechanism of action.
Q: Is it possible to customize the study design to fit my specific drug candidate?
A: Absolutely. Our NHP Ophthalmic Disease Model Development service is built around flexibility. We will work closely with your team to tailor every aspect of the study, from the administration route to the specific endpoints measured, ensuring the data you receive is exactly what you need to move your project forward.
Q: What if our therapeutic needs to be administered in a non-standard way, like a new surgical procedure?
A: Our team has extensive experience with a variety of administration techniques. We can expertly handle novel surgical or delivery methods and provide real-time monitoring to assess safety and efficacy. Our goal is to simulate the clinical environment as closely as possible, providing you with confidence in your approach.
Q: We're concerned about the cost and timeline. How can we ensure the project stays on track?
A: We provide a clear, fixed-price proposal and a detailed project timeline from the outset. Our dedicated project managers provide regular updates, and our transparent communication ensures you are always in the loop. We focus on efficiency and scientific accuracy to provide the most value for your investment. We encourage you to contact us for a detailed discussion about your specific needs.
Contact Us
Creative Biolabs is your trusted partner in ophthalmic drug development. Our NHP Ophthalmic Disease Model Development service provides a critical, high-fidelity platform that accelerates your research and strengthens your path to market. To learn more about how our NHP ophthalmic models can transform your preclinical research, please reach out to our team of experts. We are ready to provide a customized quote and discuss your project in detail.
Reference
- Zhong, Liping, et al. "Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver." Signal Transduction and Targeted Therapy 6.1 (2021): 411. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41392-021-00799-7